Ryan P Hickson Ashley L Cole Stacie B Dusetzina
10.18553/jmcp.2019.25.1.072
J Manag Care Spec Pharm
2019 Jan;25(1):72-79.
author_manuscript
https://pubmed.ncbi.nlm.nih.gov/30589625/
Diabetes Mellitus, Type 2 / drug therapy Dipeptidyl-Peptidase IV Inhibitors / therapeutic use Drug Labeling Myocardial Infarction / chemically induced Pioglitazone / therapeutic use Rosiglitazone / therapeutic use
Diabetes Mellitus, Type 2 / drug therapy Dipeptidyl-Peptidase IV Inhibitors / therapeutic use Drug Labeling Myocardial Infarction / chemically induced Pioglitazone / therapeutic use Rosiglitazone / therapeutic use Adult Humans Middle Aged Pioglitazone / adverse effects Retrospective Studies Rosiglitazone / adverse effects Young Adult Dipeptidyl-Peptidase IV Inhibitors Rosiglitazone Pioglitazone
PMC6426122
30589625
Implications of Removing Rosiglitazone's Black Box Warning and Restricted Access Program on the Uptake of Thiazolidinediones and Dipeptidyl Peptidase-4 Inhibitors Among Patients with Type 2 Diabetes
2019